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STUDIES OF AN UNUSUAL TRANSTHYRETIN PROTEIN (TTR GLU51_ 
SER52DUP) ASSOCIATED WITH FAMILIAL AMYLOIDOSIS 
HASSAN A. ABDULLAHI 
ABSTRACT 
Transthyretin-related amyloidosis (ATTR) is a disease involving the 
formation of a misfolded transthyretin (TTR) protein and resulting insoluble 
aggregates that deposit in extracellular regions of various tissues and organs. 
There are hereditary forms of the disease, referred to as ATTRm, and more than 
100 TTR amyloid-forming mutants have been reported. 
The major goal of this work was to analyze the biochemical and 
biophysical properties of a unique and recently identified TTR mutant protein, 
TTR Glu51_Ser52dup, found in a patient with ATTRm. Unlike other single 
nucleotide replacements that have been described as amyloidogenic, the gene 
abnormality in the present case is the first identification of a TTR duplication 
mutation. The patient with TTR Glu51_Ser52dup exhibited an extremely 
aggressive form of ATTRm; clinical symptoms included peripheral neuropathy at 
baseline evaluation and rapid disease progression to early death from 
pneumonia and congestive heart failure. We hypothesized that the TTR 
Glu51_Ser52dup variant would be less stable than the wild-type protein and 
similar in stability to another highly amyloidogenic mutant, TTR L55P; moreover, 
the highly unstable nature of this TTR variant would provide a basis for 
understanding the extremely aggressive clinical phenotype observed in this case. 
  vii 
Using Escherichia coli (E. coli) as an expression system and an 
appropriately modified expression vector, we produced histidine-tagged 
recombinant human TTR Glu51_Ser52dup protein in high yield and purified to 
homogeneity. Structural and stability studies were performed by circular 
dichroism (CD) spectroscopy and SDS-PAGE analysis. We demonstrated that 
TTR Glu51_Ser52dup was less stable than the wild-type or L55P proteins when 
measured under different types of denaturing conditions, including thermal and 
chemical stress. The presence of diflunisal, a drug that stabilizes tetrameric TTR 
and is currently approved for treatment of ATTRm, was also investigated; our 
results indicated that diflunisal stabilized the TTR Glu51_Ser52dup protein. 
Collectively, the data obtained from these studies suggest that 
Glu51_Ser52dup is one of the least stable and most amyloidogenic TTR variant 
described to date. Future investigations are necessary to determine which 
specific structural elements of the protein destabilize the TTR tetramer, and 
precisely characterize the binding of small molecules, including diflunisal, to the 
protein. 
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INTRODUCTION 
 
Protein Folding and Disease 
Correct folding is essential for proper functioning of a protein; 
consequently, when this process is compromised, disease and injury can result. 
Systems exist in the organism to allow correctly folded proteins to remain, and 
improperly folded ones to be repaired or discarded (Stefani, 2008). The native 
state of the protein is achieved through a multistep pathway which includes 
formation of a number of intermediate folded states; these transitions have been 
described as a funnel-like pathway where the protein arrives at its native state 
and stability when the free energy of the conformation is minimized (Merlini & 
Bellotti, 2003). The misfolded state of a protein, caused by expression of a gene 
mutation or dysfunction of a normal process, is achieved in a similar fashion. The 
proteinopathies, such as Creutzfeldt-Jakob disease, Alzheimer's disease, 
Parkinson's disease, prion disease, and the systemic amyloidosis, are all 
examples of pathologies caused by misfolded proteins that have not been 
effectively refolded or discarded (Dobson, 2003).  
At the cellular level, proteins are synthesized from genetic information 
encoded in the DNA on ribosomal complexes and transported to the endoplasmic 
reticulum (ER) where folding commences (Dobson, 2003).  Secondary and 
tertiary structures arise as the protein finds a stable conformation. Chaperones 
aid in the process of folding by increasing the efficiency of folding, likely by 
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preventing competing reactions, notably aggregation (Dobson, 2003). In proteins 
that are partially folded or in misfolded states, hydrophobic amino acid residues 
may be exposed instead of buried within a protected core that excludes H2O; this 
causes an increased propensity of the protein to aggregate and in certain cases, 
can ultimately lead to amyloid fibril formation (Kim et al., 2013). In the amyloid 
diseases, misfolded aggregates can arise either as a consequence of a genetic 
mutation or some other, as yet undetermined, extrinsic factor(s) that causes the 
precursor proteins to assume a pathologic or amyloidogenic state (Merlini & 
Bellotti, 2003). One such amyloid-forming protein is the plasma circulating 
protein, transthyretin (TTR); the misfolding, aggregation, and fibrillization of TTR 
is linked to the presence of mutations in coding regions of the TTR gene (familial 
or inherited, ATTRm) or associated with the process of aging in TTR amyloid 
disease featuring deposits composed of the wild-type protein (acquired, 
ATTRwt). 
Transthyretin 
Transthyretin (TTR), formerly known as prealbumin, is a plasma 
circulating protein involved in the transport of thyroxine (T4) and retinol-binding 
protein attached to retinol (Cascella et al., 2013). The protein is comprised of four 
identical subunits, each approximately 14 kDa in size; the molecular weight of the 
tetramer is 55 kDa. TTR is a secretory protein expressed mainly by hepatocytes 
and found in plasma normally at concentrations of 150-400 g/mL (Buxbaum & 
Reixach, 2009). Minor sites of production include the choroid plexus and eye; in 
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cerebrospinal fluid, TTR levels are typically 10-40 g/mL (Herbert et al., 1986). 
Each monomer of TTR is composed of 127 amino acid residues that normally 
fold as 8 beta strands arranged in a sandwich-like conformation of two separate, 
four beta strand, sheets (Azevedo et al., 2013). The TTR homotetramer is 
extremely stable, and in vitro studies have shown that dissociation of the 
subunits requires non-physiologic conditions such as an acidic environment, 
elevated temperature, or chemical denaturant (Robinson and Reixach, 2014). 
While the thyroid hormone, T4, is mainly transported in blood by thyroxine-
binding globulin, a minor carrier of the molecule is TTR. The interaction between 
native state or tetrameric TTR and the ligand occurs in a binding pocket created 
by one of the two TTR dimer-dimer interfaces (Foss et al., 2005). The 
energetically weaker of the two interfaces contains the hydrophobic T4 binding 
cavities wherein the hormone exhibits negative cooperativity once bound, making 
the second binding site less accessible (Johnson et al., 2005). T4-binding to TTR 
was shown to greatly stabilize the native state of the protein (Foss et al., 2005). 
Based on this finding, a therapeutic strategy targeting the tetrameric form of TTR 
was developed; consequently, the focus of much research over the past couple 
of decades has been the search for compounds that can selectively bind in the 
T4 attachment sites of TTR and prevent subunit dissociation of the protein. While 
many compounds have been identified, a select few have demonstrated non- or 
positively cooperative binding (Johnson et al., 2005). One agent that effectively 
bound to and stabilized tetrameric TTR was the non-steroidal anti-inflammatory 
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drug (NSAID), diflunisal (Tojo et al., 2006). Repurposed for clinical use in 
ATTRm, diflunisal was tested in an international, placebo-controlled study of 
patients with familial TTR amyloidosis featuring neuropathy; data from the two-
year trial showed significant reduction of neurological indicators suggesting a 
slowing of disease progression (Berk et al., 2013). Tafamidis, another small 
molecule stabilizer of native (tetrameric) TTR, has also been shown to reduce 
neurological progression in patients with ATTRm and has drug approval status in 
Europe, but not in the United States (Coelho et al., 2012). 
 Besides being a transporter of vitamin A and thyroid hormone, TTR may 
have other functions in organisms. TTR levels have been recently linked to 
memory and cognitive functions (Fleming et al., 2009). Studies have shown that 
TTR knock out mice have increased locomotor activity, decreased anxiety-like 
behaviors, spatial memory impairment, and accelerated cognitive impairment 
associated with aging (Sousa et al., 2004; Sousa et al., 2007). 
Amyloidosis 
Amyloidosis is a term that refers to a heterogeneous group of protein 
misfolding diseases commonly featuring the accumulation of insoluble amyloid 
protein fibrils in various organs and tissues throughout the body. These 
pathologies can be loosely classified based on the location(s) of the amyloid 
deposits, either as localized with one site of involvement found close to the 
production of the amyloid precursor protein or systemic when multiple 
tissues/organs distally situated from the expression site are involved. Acquisition 
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of disease can be random (sporadic) or hereditary (familial), and to date, more 
than 30 separate human proteins have been identified as amyloidogenic (Sipe et 
al., 2016). Some of the more commonly diagnosed forms of amyloidosis are 
caused by monoclonal immunoglobulin light chain (AL amyloidosis), serum 
amyloid A protein (AA amyloidosis), and TTR (ATTR amyloidosis) (Wechalekar 
et al., 2016). These different forms of amyloidosis provide unique challenges in 
diagnosis and treatment as the disease manifestations can be quite diverse 
among individuals, clinical features are frequently overlapping between amyloid 
disease types, and in some cases, onset and progression of the disease may 
take many years. 
Localized forms of amyloidosis include Alzheimer’s disease, Parkinson’s 
disease, Huntington’s disease, and type 2 diabetes (Abedini and Schmidt, 2013). 
All of these feature amyloid deposits limited to a single organ; in the examples 
cited, the accumulation of amyloid is restricted to the brain in the first three 
diseases, while amyloid infiltration occurs in the pancreas in type 2 diabetes. 
Despite demonstration of amyloid plaque buildup in these diseases, it still is 
unclear whether the amyloid deposits are actually the pathological cause or an 
effect of the process (Pepys, 2006).  
In the systemic amyloidoses, multiple organ systems and tissues are 
infiltrated and disrupted by the amyloid deposits. Currently, it is generally held 
that AL amyloidosis is the most commonly diagnosed form of amyloid disease, 
but other types including those associated with TTR (ATTRm and ATTRwt) are 
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becoming increasingly recognized (Wechalekar et al., 2016). In both the AL and 
TTR disease types, the majority of cases feature amyloid deposits in cardiac 
tissue which results in cardiomyopathy and heart failure, and contributes to the 
highest number of patient deaths (Hoyer et al., 2008). The diagnosis of amyloid 
in patients with myocardial amyloid deposits is usually made by cardiac MRI and 
right ventricular biopsy showing positive Congo red staining (Hoyer et al., 2009; 
Sharma and Howlett, 2013). The prognosis for patients with cardiac involvement 
is not good especially in AL amyloidosis, as this has been reported to be the 
worst prognostic factor (Sharma and Howlett, 2013). Median survival is less than 
6 months in untreated patients, which makes early diagnosis and treatment 
critical (Kyle & Gertz, 1995; Ando et al., 1993). Almost every organ system is 
involved to some extent in cases of systemic amyloidosis including the kidneys, 
central and peripheral nervous system, and respiratory system. This makes it 
extremely difficult to diagnose and manage these diseases, as symptoms mimic 
many other pathological conditions. 
The term “amyloid” was first used in 1853 by Rudolph Virchow who 
characterized unknown extracellular deposits as being “starch-like” (Virchow, 
1854). Amyloid ultrastructure was first determined using electron microscopy and 
reported in 1959 (Cohen and Calkins, 1959). Irrespective of the fibril protein 
constituent, all amyloid deposits were found to have common tinctorial properties 
and consist of morphologically identical fibrils (Figure 1). These fibrils 
demonstrate apple-green birefringence under polarized light when stained with 
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Congo red and viewed by light microscopy (Figure 1A) (Giorgadze et al., 2004). 
In addition, the ultrastructure of amyloid features non-branching fibrils of varying 
lengths (Figure 1B) that display an x-ray diffraction pattern consistent with an 
antiparallel beta-sheet configuration. 
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Figure 1.  Histological and ultrastructural criteria defining amyloid 
deposits. (A) Congo red binding viewed by standard (left panel) and polarized 
(right panel) light microscopy showing positive staining and characteristic apple-
green birefringence. (B) Ultrastructure featuring non-branching, variable length, 
~10 nm diameter fibrils demonstrated by electron microscopy. Arrow indicates 
fibril associated protein, serum amyloid P-component arranged in a stacked 
structure. 
 
A 
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While the demonstration of congophilia and green birefringence by light 
microscopy has been the gold standard for identifying amyloid deposits, newer 
characterization techniques have also been shown to be useful (Sipe et al., 
2016). Ex vivo or in vitro generated amyloid fibrils can be visualized using either 
transmission electron microscopy (TEM) or atomic force microscopy (AFM). 
Ultrastructurally, amyloid fibrils formed from variably sized proteins, i.e. 
polypeptide chains containing different numbers of amino acid residues, have 
been shown to have similar diameters (~10 nm) (Serpell et al., 2000). Solid-state 
nuclear magnetic resonance spectroscopy (SSNMR) and x-ray crystallography 
techniques have greatly advanced the structural information pertaining to amyloid 
fibrils; the distinct morphological features of amyloid fibrils and prefibrillar forms 
have been elucidated through SSNMR and TEM spectroscopy, and have been 
found in amyloidogenic proteins such as Aβ protein (Petkova et al., 2005). 
Recent studies using fluorescence spectroscopy have proved useful in 
uncovering interactions between amyloidogenic proteins and cellular 
membranes, e.g. investigations have shown that aggregated forms of TTR 
increase membrane fluidity and this process has been suggested as a possible 
mechanism leading to cell death (Munishkina and Fink, 2007). 
Amyloid deposits, in addition to the fibril protein constituent, have several 
non-fibrillary components that are always found in association with the deposits. 
These include glycosaminoglycans (GAGs) and the glycoprotein, serum amyloid 
P-component (SAP, see arrow in Figure 1B) (Wechalekar et al., 2016). 
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Discovery of these fibril-associated components, common to all amyloid deposits, 
have provided diagnostic and therapeutic avenues. SAP scintigraphy is an 
imaging technique where radio-labeled SAP is monitored for specific organ 
uptake, as SAP binds to the amyloid deposits (Hazenberg et al., 2004). 
Eprodisate, a molecule that targets the glycosaminoglycan binding site on 
amyloid fibrils has been shown to slow the progression of AA amyloidosis-related 
renal disease (Dember et al., 2007). Other specific treatments such as 
chemotherapy for AL amyloidosis and anti-inflammatory drugs for AA 
amyloidosis have also shown promise (Comenzo et al., 1998; Gillmore et al., 
2001; Skinner et al., 2004) 
 
Transthyretin-related Amyloidosis 
Transthyretin-related amyloidosis (ATTR) is a systemic disease 
characterized by the extracellular deposition of amyloid fibrils composed of TTR. 
Despite having wide-ranging clinical phenotypes, ATTR is believed to have a 
common mechanism of amyloidogenesis. There are familial and an acquired 
forms of the disease; TTR amyloidosis related to mutant forms of the protein 
results from inherited TTR gene coding region nucleotide alterations (ATTRm) 
and wild-type TTR-associated amyloidosis (ATTRwt), is an age-related disease 
formerly known as senile systemic (SSA) or senile cardiac (SCA) amyloidosis. It 
is generally accepted that TTR amyloidogenesis is initiated by destabilization of 
the native TTR protein and dissociation of the non-covalently bound subunits to 
individual monomers; this is the rate-limiting step in the process (Hurshman 
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Babbes et al. 2008). Once dissociation occurs, the monomeric forms become 
misfolded and assume non-native conformations that favor self-aggregation; the 
association of misfolded subunits is likely due to exposure of hydrophobic 
regions which are buried deep with the properly folded protein so as to exclude 
H2O (Hurshman Babbes et al. 2008). The formation of oligomeric, pre-fibrillar 
forms of TTR progresses to development of amyloid filaments and ultimately, 
insoluble fibrils which constitute the tissue-deposited amyloid (Figure 2). 
  
 12 
 
 
Figure 2.  TTR Fibril formation pathway.  
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ATTRm is the most frequently occurring hereditary systemic amyloidosis; 
while there are endemic areas around the world, the disease is thought to occur 
at a prevalence of 1:1000 (de Larrea et al., 2015; Ruberg and Berk, 2012). The 
sporadic form of the disease (ATTRwt) results from misfolding of the wild-type 
TTR protein in the absence of a mutation. Amyloid deposits in ATTRwt are most 
commonly, but not exclusively, found in the heart (Westermark et al., 1990). 
Cardiac amyloid deposition of wild-type TTR was reported at autopsy in a quarter 
of individuals over 80 years of age and found to be the cause of death in 10% of 
cases (Cornwell GG et al., 1983; Tanskanen et al., 2008). 
Based on major clinical phenotype, ATTRm can be divided into TTR-
related familial amyloidotic polyneuropathy (FAP) and TTR-related familial 
amyloidotic cardiomyopathy (FAC). FAP patients feature amyloid deposits found 
in various organs, but the disease manifests as symptoms of peripheral and 
autonomic neuropathy (Almeida et al., 2004). The most prevalent amyloidogenic 
TTR mutant associated with FAP involves substitution of the valine residue at N-
terminal position 30 with a methionine, TTR-V30M (Almeida et al., 2004). Clinical 
onset in patients with FAP usually begins with sensorimotor peripheral 
neuropathy in the lower limbs and progression to sensory impairment (mainly 
pain/temperature sensation), as well as autonomic dysfunction including 
dyshidrosis, sexual impotence, gastrointestinal disturbances, and orthostatic 
hypotension (Ando et al., 1993, Araki et al., 1968). The disease was first 
described by a neurologist in Portugal more than 60 years ago (Andrade, 1952). 
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Since that initial report, patients with these clinical features have primarily been 
identified in Portugal, Japan, and Sweden (Conceição & De Carvalho, 2007) 
One of the most aggressive, i.e. rapidly progressing, forms of ATTRm is 
associated with TTR L55P; this variant is the gene product of a TTR point 
mutation in exon 3 at codon 55 which translates to leucine replaced by proline at 
N-terminal residue 55 (Cardoso et al., 2002). ATTRm related to L55P is a very 
rarely occurring disease with a clinical phenotype that features early onset in the 
second and third decades of life (Sousa et al., 2002). In vitro studies using 
recombinantly-generated TTR L55P have demonstrated lower structural stability 
in the protein and more rapid formation of aggregates by this variant, compared 
to the wild-type and V30M proteins (Jacobson et al., 1992; Kon et al., 2015). 
ATTR Treatment and Current Therapeutic Strategies 
Liver transplantation has been the main treatment option for patients with 
familial amyloidosis since the 1990s; the strategy is based on removing the 
source of the mutant TTR. Until recently, this was the major disease intervention 
specifically approved for patients diagnosed with ATTR, but this option is 
primarily for younger patients with the V30M or other non-cardiac associated 
mutations who are diagnosed early in the course of the disease (de Carvalho et 
al., 2002; Herlenius et al., 2004). Prior to studies with the TTR stabilizer, 
diflunisal, liver transplantation was the only treatment reported to halt the clinical 
progression of FAP (de Carvalho et al., 2002). 
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In the past, disease management was frequently limited to utilization of 
drugs that controlled the symptoms patients were experiencing. However, a 
number of different therapeutic strategies targeting the various stages of TTR 
amyloid formation have provided the rationales for development and clinical 
testing of an assortment of agents (Figure 3). These potential drugs offer 
patients the promise of therapeutic options.  
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Figure 3.  Therapeutic strategies in ATTR.   
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Diflunisal, a repurposed, nonsteroidal anti-inflammatory drug (NSAID), is 
FDA approved to treat ATTR (Berk et al., 2013). Structurally similar to T4, 
diflunisal is believed to bind and occupy the same site on TTR that the thyroid 
hormone can occupy (Johnson et al., 2005). Selective binding and stabilization of 
the TTR tetramer have been a major focus of drug development for ATTRm until 
most recently. Studies of patients with familial amyloidotic polyneuropathy have 
shown treatment with diflunisal is associated with inhibition of disease 
progression, and preservation of quality of life (Almeida et al., 2004). Another 
drug, Tafamidis, has been approved for use by the European Medicines Agency. 
In a phase 3 clinical trial, neuropathy in tafamidis-treated patients with familial 
amyloidosis (V30M mutation) showed reduced progression over 18 months 
compared to patients treated with a placebo (Coelho et al., 2012). 
Thesis Research Objectives 
Our goals for the research detailed in this thesis were to generate a 
recombinant TTR protein with the novel variant sequence, Glu51_Ser52dup, and 
utilize this replicate to explore the stability and structural features of this 
amyloidogenic protein. The mutant TTR was identified in a patient treated at the 
Boston University Amyloidosis Center. The mutation was associated with a 
severely aggressive form of familial amyloidotic polyneuropathy. A positive 
diagnosis of amyloidosis was established by Congo red staining of a tissue 
sample (abdominal fat aspirate) from the patient and the amyloid fibril protein 
was identified as TTR by mass spectral analysis. Based on the clinical 
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information, we hypothesized that amyloidogenic TTR Glu51_Ser52dup protein 
would be highly unstable compared to wild-type and other pathologic mutants. In 
addition, our plan was to assess the effects of diflunisal, a kinetic stabilizer of the 
TTR tetramer, on the stability of the TTR mutant in vitro. We postulated that 
diflunisal would have less of a stabilizing effect on the TTR Glu51_Ser52dup 
mutant compared to native and variant forms of TTR. Our specific aims were: 
1) To generate recombinant TTR Glu51_Ser52dup in high yield and 
purified to homogeneity for biochemical and biophysical analyses. 
2) To measure the stability of the variant protein under denaturing 
conditions and compare these data to similar measurements obtained 
on wild-type and L55P TTR proteins. 
3) To assess the effects of diflunisal on the stabilities of TTR 
Glu51_Ser52dup, wild-type, and L55P in experiments run in parallel 
with those in Aim 2. 
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METHODS 
Chemicals and Reagents 
Primary antibody (rabbit anti-human polyclonal TTR) was purchased from DAKO 
(Troy, MI). Secondary antibody (HRP-conjugated, goat anti-rabbit polyclonal) 
was purchased from Santa Cruz Biotechnology (Dallas, TX). Glutaraldehyde and 
diflunisal were purchased from MP Biomedicals (Santa Ana, CA). All other 
materials were purchased from Applied Biosystems (Foster City, CA), Thermo 
Scientific (Waltham, MA), Invitrogen (Carlsbad, CA) or Sigma (St. Louis, MO), 
and were all of the highest grade available. 
Clinical Samples 
All clinical samples and data used in this study were from the Boston University 
Amyloidosis Center serum repository with approval of the Boston University 
Medical Center Institutional Review Board.  
BCA Serum Assay 
Protein concentration in the serum samples was calculated using a BCA Protein 
Assay kit (Thermo Scientific). BCA Protein assay relies on the reduction of 
copper in an alkaline medium for the colorimetric detection and quantitation of 
total protein. Detection is carried out at 570 nm in a spectrophotometer. Bovine 
serum albumin (BSA) was used as the standard protein to create a reference 
curve for calculating the concentration of the unknown protein. All samples and 
references were mapped were analyzed in a Costar 3596 cell culture plate 
(Sigma). The standard protein was diluted to 2000, 1500, 1000, 750, 500, 250, 
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125. 25, and 0 µg/mL. Serum samples to be tested were initially diluted by a 
factor of 1:25 and 1:100. Ten µL of each diluted serum sample and 15 µL of 
deionized water were combined; 25 µL of the known BSA standard were 
compared as reference. To each well, 200 µL of the working reagent was added, 
and the plate was shaken for 30 seconds. The plate was covered with aluminum 
foil and incubated at 37 °C for 30 min. The absorbance of each sample in the 
plate was measured at 570 nm using a CFX96 Real-Time Thermal Cycler (Bio-
Rad). A standard curve was generated based on the known concentrations of the 
BSA standards, and was used to calculate the concentration of total protein in 
the serum. 
Western Blot 
Twenty µg of whole serum protein per lane were analyzed by western blot, 
alongside a control serum sample.  Twenty-five µL of serum sample was mixed 
with 40 µL of 10% SDS and heated at 98 °C for 5 minutes. 0.88-2.5 µL of the 
serum sample was added to 20 µL of 2X Tricine sample buffer (Bio-Rad), 10 µL 
of 10% SDS, and 9.12-7.5 µL of deionized water for a total volume of 40 µL. 
Samples were loaded onto a Novex 16% Tricine Protein 10 well gel (Invitrogen); 
a protein ladder (Spectra Broad Range Protein Ladder, Pierce) was also run on 
each gel.  
 Proteins were transferred from the gel onto a polyvinylidene difluoride 
(PVDF) membrane using a wet transfer method in transfer buffer (1.66 g Tris 
base, 7.2 g Glycine, 100 mL MeOH, total volume 500 mL, pH 8.4). The protein 
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transfer was done at 4 °C at 30 V overnight. The following day, the membrane 
was removed and placed in a blocking solution (5% dried milk in TBST) for 2 
hours at room temperature. The membrane was washed 3 times in TBST and 
incubated with rabbit anti-human polyclonal TTR primary antibody (DAKO) at a 
1:2000 dilution in 2.5% milk and TBST for 2 hours. Next, the membrane was 
washed again 3 times in TBST before incubation at room temperature with goat 
anti-rabbit HRP conjugated secondary antibody (Santa Cruz) at a 1:2000 dilution. 
After 1 hour, the membrane was washed 3 times in TBST and developed using 
ECL Plus Western Blotting Detection System (Pierce). 
Site Directed Mutagenesis 
A synthetic human TTR gene containing altered codon usage for expression in E. 
coli cloned into the pQE-30 plasmid (Qiagen) (Kingsbury et al., 2007) was used 
for construction of the TTRdupES variant. Two primers containing the target 
mutations were designed. The gene with the appropriately modified structure 
(insertion of six nucleotides encoding for two amino acids, Glu51 and Ser52) was 
successfully constructed using QuikChange II Site-Directed Mutagenesis Kit 
(Agilent Technologies).  
The sequences of the mutagenic primers are shown below with mutation 
site nucleotide insertions underlined: 
(forward) 5’-CCGGTAAAACCTCCGAATCCGAATCCGGTGAACTGCACGG-3’ 
(reverse) 5’-CCGTGCAGTTCACCGGATTCGGATTCGGAGGTTTTACCGG-3’. 
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These primers were then used for amplification of the region by polymerase 
chain reaction (PCR) as detailed in Table 1. 
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Table 1: Polymerase chain reaction protocol 
Description Amount 
DNA (MK(6H)GH-TTRdupES/pQE-
30), 10ng 
2µL 
10X reaction buffer 2.5µL 
TTRdupESfor (125ng) 6.7µL 
TTRdupESrev (125ng) 6.1µL 
dNTPS 0.5µL 
ddH2O 7.2µL 
Pfu Ultra HF DNA 
Polymerase(2.5ng/µL) 
0.5µL 
Total Volume 25.5µL 
 
PCR Setup: 
PCR conditions 
 T (C) Time 
1 95 30 secs 
2 95 30 secs 
3 55 1 min 
4 68 6 min 
5 2-5 17 times 
6 4 Forever 
7 End  
 
The original DNA in the mixture was digested using 0.5µL of DpnI enzyme and 
incubated at 37 °C for 1 hr. 
Plasmid DNA Gel Electrophoresis 
The presence of plasmid was confirmed by running the PCR product on a 1.2% 
agarose gel with a 10kb ladder. Samples were loaded and run at 150 V in TAE 
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buffer; the reaction product was confirmed by identifying an appropriately sized 
band corresponding to 3-4 kb (3.4 kb plasmid). 
Transformation of E. coli XL1-Blue Supercompetent Cells 
Plasmid DNA (TTRdupES/pQE-30) was transformed into XL1-Blue cells. Fifty µL 
of XL1-Blue cells were thawed on ice for 10 minutes before 8 µL of plasmid DNA 
was added and mixed with the cells. The mixture was incubated on ice for 20 
minutes, heat shocked at 42 °C for 45 seconds, and incubated on ice for another 
2 minutes. SOC media (400 µL) was added to the mixture and the tube was 
incubated at 37 °C for 1 hour at 250 rotations per minute. Following incubation, 
200 µL of the solution was plated on an LB plate supplemented with ampicillin 
(100 µg/mL) while the remaining 250 µL was plated on another LB/ampicillin 
plate. All plates were incubated at 37 °C overnight.  
DNA Isolation 
The plasmid DNA was isolated from the cell culture using the Wizard ® Plus SV 
Minipreps DNA Purification System (Promega). A single colony from each plate 
was inoculated into a separate cell culture tube containing 5mL of LB broth and 
ampicillin (100 µg/mL). The tubes were left to incubate overnight at 37 °C with 
shaking at 250 rpm. The following day bacterial cells were harvested through 
centrifugation in a table-top microcentrifuge (top speed for 3 minutes at room 
temperature). The supernatant was discarded and bacterial cell pellets were re-
suspended in 250 µL of Cell Resuspension Solution. The resulting solution was 
transferred into a micro-centrifuge tube, 250 µL Cell Lysis Solution was added, 
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and the tube was inverted 4 times to ensure complete mixing. Ten µL of alkaline 
protease was then added to the tube, the tube was inverted 4 times for complete 
mixing, and left at room temperature for 5 minutes. Next, 350 µL of Neutralization 
Solution was added and the tube was inverted 4 times for complete mixing. The 
tube was centrifuged in a table-top microcentrifuge (top speed for 10 minutes) 
and the supernatant was pipetted onto a spin column with collection tube; the 
spin column was subsequently centrifuged (top speed for 1 minute) and the flow-
through in the collection tube discarded and replaced. The next step involved 
adding 750 µL of Wash Solution (EtOH added) to the tube followed by 
centrifugation (top speed for 1 minute). The flow-through was discarded and 
another 250 µL of Wash Solution was added; the tube was centrifuged for 1 
minute and again, the resulting flow-through was discarded. The tube was 
centrifuged for 2 minutes and the flow-through subsequently discarded. DNA in 
the spin column was finally eluted with 100 µL of water into a clean 
microcentrifuge tube through centrifugation (top speed for 1 minute). The 
presence of plasmid in the cell culture from selected colonies was confirmed on a 
1.2% agarose gel run with a 10 kb ladder. Samples were loaded and run at 150 
V in TAE buffer. The reaction product was confirmed by identifying a band 
around 3-4 kb (3.4kb plasmid). 
DNA Concentration Determination and Sequencing 
To determine DNA concentration, the absorbance of the collected DNA was 
measured at 260 nm in a Cary 300 UV-Vis spectrophotometer (Agilent).  DNA 
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sequencing of the complete coding region in the expression plasmid was 
performed to verify that the correct insertion was present. Alignment of DNA 
sequences for wtTTR and TTRdupES are shown: 
 
Transformation into E. coli M15[pREP4] Cells for Expression.  
Eight µL of the purified plasmid DNA was added to 50 µL of thawed M15[pREP4] 
cells. The mixture was incubated on ice for 20 minutes, heat shocked at 42 °C for 
90 seconds, and incubated on ice for another 2 minutes. PSI broth (500 µL) was 
added to the mixture and the tube was incubated at 37 °C for 90 minutes at 250 
rpm. Fifty and 100 µL of the culture were plated on LB plates supplemented with 
ampicillin (100 µg/mL) and kanamycin (25 µg/mL), and the plates were incubated 
at 37 °C overnight. 
Protein Expression and Purification 
The transformed E. coli M15 (pREP4) cells containing the recombinant TTR with 
N-terminal 6-histidine tags were prepared for expression. A single isolated colony 
from each plate was inoculated into test tubes containing 4.5 mL of LB broth 
supplemented with ampicillin (100 µg/mL) and kanamycin (25 µg/mL). The test 
tubes containing the cell cultures were incubated at 37 °C with shaking at 225 
rpm. The next day, four flasks were prepared, each containing the cell cultures 
TTRdupES …CCGGTAAAACCTCCGAATCCGAATCCGGTGAACTGCACGG… 
wtTTR        … CCGGTAAAACCTCCGAATCC -  - - - - - GGTGAACTGCACGG… 
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inoculated into 500 mL of autoclaved LB broth supplemented with ampicillin (100 
µg/mL) and kanamycin (25 µg/mL). The flasks containing the mixtures were 
incubated at 37 °C with shaking at 225 rpm for 3 hours until the optical density 
(OD) exceeded 0.6 at 600 nm. Next, 500 µL (for a final concentration 1mM) of β-
D-1-thiogalactopyranoside (IPTG) was added to each flask to induce expression 
of the recombinant TTR protein. After an additional 4 hours of incubation under 
the same conditions, the mixtures were centrifuged in a SLA-1500 rotor at 6,000 
rpm for 20 minutes at 4 °C. The supernatants were discarded and the cell pellets 
were stored overnight at -20 °C. 
The pellets were thawed on ice for 15 minutes before being re-suspended 
in immobilized-metal ion affinity column (IMAC) cell lysis buffer at 3 mL per gram 
wet weight. The resulting solution was supplemented with lysozyme (1 mg/mL) 
and was incubated on ice for 30 minutes. Next, the cells were sonicated in bursts 
on ice to avoid overheating until the solution appeared transparent. The solution 
was then centrifuged in a SS-34 rotor at 9,000 rpm for 30 minutes at 4 °C. 
Supernatant was transferred into 50 mL conical tubes with a syringe containing a 
0.22 µm filter. 
A 6 mL Nickel-Nitriloacetic Acid (NTA) Agarose column (Qiagen) was 
prepared and equilibrated with IMAC wash buffer. Twenty mL of the supernatant 
was loaded and allowed to flow through the column into a collection tube. The 
column was rinsed several more times with IMAC wash buffer until the optical 
density (OD) reading at 280 nm was zero. The recombinant TTR protein was 
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then eluted in IMAC elution buffer; the eluted samples with OD > 0.1 at 280 nm 
were combined. Isolated protein samples were dialyzed against 50% PBS 
solution using a 7,000 MWCO Slide-A-Lyzer cassettes (Thermo Scientific) for 3 
hours, changing the PBS every 30 minutes. 
The amount of purified recombinant TTR with N-terminal 6-histidine tag 
was determined by measuring the absorbance of the dialyzed solution at 280 nm. 
The dialyzed protein solution was aliquoted into small vials, flash frozen in a 
combination of dry ice and acetone, and stored at -150 °C until required for 
analysis. 
Subunit Exchange Procedure 
The recombinant wild-type and recombinant mutant (TTR-Glu51_Ser52dup) 
were mixed in varying amounts (3:1, 1:1, 1:3 ratios) at a total working TTR 
concentration of 0.2 mg/mL. Mixtures were incubated at 4 °C for 48 hours to 
allow for subunit exchange (Schneider, Hammarstrom, Kelly, 2001) and cross-
linked with glutaraldehyde following the protocol described below. 
Transthyretin – Diflunisal Samples 
Diflunisal (MP Biomedicals) was dissolved in a solution of 0.1% DMSO and 9.9% 
EtOH in deionized water to make a 10X stock solution (3.6 mM). Recombinant 
TTR tetramer (0.2 mg/mL equivalent to 3.6 M) was pre-incubated with 100 
molar excess of diflunisal (0.36 mM) for 2 hours at room temperature. 
Transthyretin Aggregation Studies 
TTR samples with and without diflunisal were incubated in glass vials at 80 °C for 
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0-24 hours. Aliquots were taken at time points during the incubation (0, 1, 2, 4, 
24 hours), cross-linked with glutaraldehyde, and analyzed by SDS-PAGE 
analysis as detailed in the next section. 
Protein Cross-Linking Procedure 
Five µL of 25% glutaraldehyde was added to 20 µL of protein sample and 
incubated at room temperature for 4 minutes. The reaction was quenched with 5 
µL of 7% NaBH4 in 0.1 M NaOH.  
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis Analysis 
Protein samples were mixed with 2X non-reducing sample loading buffer (125 
mM Tris-HCl, pH 6.8, 20% glycerol, 4% SDS, 0.1% bromophenol blue). The 
mixtures were boiled for 5 minutes before being loaded into 1 mm wells on a 8-
16% Tris-Glycine or 16% Tricine gel (Invitrogen) with a protein ladder standard 
(Pierce) as reference. Protein bands were visualized after developing the gel in 
GelCode Blue Stain Reagent (Thermo Scientific) for 2 hours. 
Phast Gel Analysis 
Glutaraldehyde cross-linked protein samples were mixed with 2X non-reducing 
sample loading buffer and boiled for 5 minutes employing the method described 
previously. Using the automated Pharmacia Phast System (GE, Fairfield, CT), 
samples were loaded onto a 10-15% Gradient pre-cast gel with SDS buffer strips 
located at both ends of gel.  
Circular Dichroism Spectroscopy 
Circular dichroism (CD) spectral data was obtained on a Jasco J-815 spectro- 
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polarimeter equipped with a thermoelectric temperature controller. Near UV (330-
250 nm, 1 nm bandwidth) and far UV (250-190 nm, 1 nm bandwidth) data were 
collected in 10 mm and 1 mm path length quartz cells, respectively. Far UV CD 
spectral data were smoothed using Jasco noise reduction routine and normalized 
to protein concentration. CD data are presented as mean residue molar ellipticity 
(MRE) values. Protein sample solutions were prepared at 0.2 mg/mL in PBS.  To 
measure thermal stability, protein samples were heated from 25 °C to 98 °C at 
0.1 ºC/min or 1 ºC/min measured at 215 and 220 nm.  
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RESULTS 
 
Serum samples from the patient with TTR Glu51_Ser52dup mutation show lower 
levels of transthyretin protein compared to control sample 
With the focus of the study on the characterization of a novel 
amyloidogenic TTR, we analyzed the serum samples from the patient for whom 
this novel mutation was identified. A western blot analysis of patient sera 
collected during three consecutive visits to the clinic in 2010, 2011, and 2012 
confirmed the presence of the TTR protein in all samples (Figure 4). Analysis of 
the cross-linked sera indicated the presence of TTR in the native tetrameric state 
(55 kD), as well as higher molecular weight species of complexed TTR. Serum 
TTR (prealbumin) concentrations, assessed through nephelometric analysis in 
the Boston Medical Center Pathology Clinical Laboratory, showed lower amounts 
of TTR in the patient samples compared to the control. For the patient at baseline 
and two annual follow-up visits, the serum TTR concentrations were 11 mg/dL in 
2010, 17 mg/dL in 2011, and 5 mg/dL in 2012 mg/dL; the control serum 
demonstrated a TTR level of 28 mg/dL. The patient TTR levels are below the 
range reported for healthy individuals (18-45 mg/dL, Buxbaum and Reixach, 
2009). This finding is consistent with the literature as patients with ATTRm have 
typically been found to have lower serum levels of TTR, which is even more 
pronounced with progression of disease (Buxbaum et al., 2010).  
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Figure 4.  Immunoblot analysis of patient sera from baseline and 2 annual 
follow-up evaluations.  Original serum samples and samples cross-linked with 
glutaraldehyde were evaluated.  Total protein concentration in serum was 
measured by BCA assay; serum samples with the same amount of total protein 
were subjected to SDS-PAGE followed by immunoblotting with primary (rabbit 
anti-human TTR) and secondary (goat anti-rabbit IgG-HRP) antibodies. 
 
 
 
 
 
 
 
 
 
 
 
 
1. 2010 visit  
2. 2011 visit 
3. 2012 visit 
4. Control 
Serum 
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Recombinant TTRdupES is less stable compared to wild-type and L55P TTR  
Our aim was to study the effect of the two amino acid insertion found in 
TTR Glu51_Ser52 on the structure, stability, and aggregation properties of the 
protein. Thus, we developed recombinant versions of the mutant, TTRdupES, 
and used these replicates in our biochemical and biophysical analyses. In 
addition, recombinant wild-type and L55P mutant TTR were produced and used 
to compare the unfolding and aggregation propensities of these proteins.  
The thermal stabilities of wild-type, TTRdupES, and L55P TTR were 
examined by using CD spectroscopy (Figure 5A). All CD measurements were 
obtained on TTR samples solubilized in phosphate buffer (pH 7.4) at a protein 
concentration of 0.2 mg/mL, a level within the physiological range of healthy 
subjects (Buxbaum & Reixach, 2009). The far-UV spectrum obtained for 
TTRdupES at 25 °C shows the predominantly -structured native conformation of 
TTR. Heating to 98 °C caused marked losses in the protein secondary structure. 
The ordered -sheet structure was presumed to adopt a non-native random coil 
shape. Due to observable differences in CD spectra at 25 °C and 98 °C, the 
wavelengths of 220 nm and 215 nm were selected for monitoring of the protein 
thermal denaturation. Far UV CD at 220 nm for -sheet to random coil 
conversion was recorded during sample heating from 25 °C to 98°C at different 
heating rates. The difference in slow (0.1 ºC/min) and fast (1 ºC/min) melt 
unfolding of the protein demonstrates the rate-dependent shift in melting 
transitions (Figure 5B).  
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 (A)                                                               
  (B)  
     
 
 
Figure 5.  Thermal unfolding of recombinant TTRdupES.  (A) Far UV CD 
spectra of intact TTR recorded at 25 °C and of the same protein that was heated 
to 98 °C. (B) CD melting data recorded at 220 nm during protein heating at fast 
(1 °C/min) and slow (0.1 °C/min) rates. 
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The far-UV spectra for the amyloidogenic mutants, TTRdupES and L55P 
TTR, as well as the wild-type are compared in Figure 6A. The spectra show a 
very high degree of similarity in secondary structure for all three proteins. 
Monitoring of the CD signal at 215 nm during sample heating from 25 °C to 98 °C 
allowed us to compare the transition between the folded and unfolded state for 
the wild-type, TTRdupES, and L55P TTR proteins (Figure 6B). For the thermal 
denaturation experiment, each sample was initially pre-incubated in 3M urea to 
destabilize the protein and facilitate an earlier transition into the unfolded state. 
This allowed us to visualize the entire unfolding process for all proteins involved, 
as the wild-type TTR protein has a melting temperature exceeding 98 ºC (Colon 
and Kelly, 1992). In this study, we observed a significant difference in the melting 
temperatures of the proteins with TTRdupES < L55P TTR < wild-type TTR. This 
earlier transition into the unfolded state demonstrates that TTRdupES is 
destabilized more easily than the wild-type, and even more than the highly 
aggressive L55P TTR variant (Jacobson et al., 1992; Kon et al., 2015).  
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Figure 6.  Comparison of the thermal stabilities of TTRdupES, L55P (an 
unstable variant) and wild-type proteins (stable TTR).  Thermal unfolding of 
recombinant TTRdupES, L55P, and wild-type TTR proteins were individually 
analyzed by CD; samples were pre-incubated in 3 M Urea. (A) Far UV CD 
spectra of intact proteins recorded at 25 oC. (B) CD melting data recorded at 215 
nm during protein heating at a slow (0.1 °C/min) rate. 
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Analyses of TTRdupES and wild-type TTR, and heterotetramers of the proteins 
show decreased stability with increasing ratio of TTRdupES 
 In most of the ATTRm patients, wild-type and amyloidogenic mutant TTR 
proteins are co-expressed, i.e. patients are heterozygous for the TTR gene 
mutation (Schneider, Hammarstrom, Kelly, 2001). In order to study the effect of 
the TTRdupES on the formation and stability of TTR heterotetramers, we 
performed the following studies. The TTRdupES and wild-type TTR proteins 
were mixed at different ratios and pre-incubated at 4 ºC for 48 hours to allow for 
subunit exchange and the formation of heterotetramers (Schneider, 
Hammarstrom, Kelly, 2001). Homotetramers of TTRdupES and wild-type TTR 
were concurrently incubated during that time period, and after 48 hours all 
samples were cross-linked with glutaraldehyde. Our electrophoretic analysis 
showed that wild-type TTR is present almost completely in the tetrameric state 
(55 kD); this observation demonstrates the high structural integrity of the sample 
(Figure 7). However, as the number of TTRdupES subunits increases in the 
heterotetramers, we observe a gradual diminishing in the native (tetrameric) state 
of the protein; lower molecular weight forms of TTR become easily identifiable in 
the more anodal region of the gel when the proportion of TTRdupES to wild-type 
TTR is 2:2 and 3:1. Thus, we conclude that increasing the number of TTRdupES 
subunits causes the TTR tetramers to dissociate into monomeric (14 kD) and 
dimeric (30 kD) forms. 
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Figure 7.  Electrophoretic analysis of TTRdupES and wild-type TTR 
heterotetramers.  Recombinant TTRdupES and wild-type TTR proteins were 
mixed at different ratios. Samples were pre-incubated at 4 oC for 48 hrs, cross-
linked with glutaraldehyde, subjected to SDS-PAGE, and stained with Coomassie 
Blue. 
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Thermal denaturation of TTRdupES, wild-type TTR, and mixtures of the 
two proteins in physiological conditions was measured by far-UV CD 
spectroscopy (Figure 8A). In a separate experiment, the samples were initially 
pre-incubated in 4.5 M urea to destabilize and facilitate transition, and to 
visualize the entire unfolding process (Figure 8B). The mixtures of wild-type TTR 
and TTRdupES exhibit cooperative transition which confirms the initial 
heterotetramer formation after pre-incubation of two variants. Heterozygous 
protein denaturation can occur gradually (cooperatively) or happen in more than 
one transition state (Clark, 2005). Observed cooperative transition likely indicates 
that subunit exchange did occur. The heterotetramers undergo thermal unfolding 
at significantly lower temperatures compared to pure wild-type TTR tetramer (> 
98 ºC). This finding demonstrates that the presence of even one TTRdupES 
mutant subunit in the heterotetramer (TTRdupES: wtTTR is 1:3) is sufficient for 
major destabilization of the entire tetramer. 
The SDS-PAGE analysis of TTR homo- and heterotetramers, heated to 80 
°C, showed a decrease of tetrameric state (55 kD) within 4 hours with a 
coincident increase in dimeric (30 kD) and monomeric (14 kD) forms of TTR 
(Figure 9). This effect is more pronounced in mixtures with a high content of the 
TTRdupES illustrating the characteristic instability of the mutant protein.  
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Figure 8.  Thermal denaturation of TTRdupES and wild-type TTR mixtures. 
Protein sample mixtures of TTRdupES and wild-type TTR were pre-incubated at 
4 oC for 48 hours to allow formation of heterotetramer. Samples were (A) slowly 
(0.1 °C/min) heated in PBS or (B) pre-incubated in 4.5 M urea for 1 hour and 
heated at the rate of 1 °C/min. CD melting data were recorded at 220 nm during 
protein heating. 
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Figure 9.  Electrophoretic analysis of TTRdupES and wild-type TTR 
mixtures.  TTRdupES and wild-type TTR proteins were pre-incubated at 4 oC for 
48 hours to form heterotetramers. The samples were subsequently incubated at 
80 °C with shaking at 200 rpm. At indicated time points samples were cross-
linked with glutaraldehyde and subjected to SDS-PAGE followed by Coomassie 
staining. 
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Diflunisal stabilizes the quarternary structures of TTRdupES, TTR L55P, and 
wild-type TTR proteins 
Diflunisal is a non-steroidal anti-inflammatory drug (NSAID) repurposed to 
treat patients with FAP amyloidosis. We investigated the stabilizing effect of 
diflunisal on recombinant TTRdupES under stress conditions. TTRdupES, wild-
type TTR, and L55P TTR, in the presence and absence of diflunisal at a 100 
molar excess of drug, were incubated at 80 ºC for 24 hours. Samples were cross-
linked before and after incubation (Figure 10). Diflunisal, pre-incubated with 
TTRdupES (time point 0), appears to stabilize the native tetrameric state of the 
protein shifting the equilibrium from the monomeric (14 kD) and dimeric (30 kD) 
forms to the tetrameric (55 kD) state. After 24 hours at 80 ºC, the tetrameric form 
of TTRdupES in the absence of diflunisal is dissociated and the high molecular 
weight oligomeric species are formed; however, TTRdupES incubated with 
diflunisal preserves the tetrameric state of the protein. For the wild-type and 
L55P TTR proteins, when diflunisal is absent, the tetramers (55 kD) begin to 
dissociate into dimers (30 kD) and monomers (14 kD) after 24hrs of incubation; 
conversely, the presence of diflunisal prevents the tetramer dissociation of both 
the wild-type and L55P proteins. Interestingly, the stabilizing effect of diflunisal 
appeared to be much more pronounced on the conformation of the TTRdupES 
mutant compared to wild-type and L55P TTR. 
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Figure 10.  TTRdupES, wild-type TTR, and L55P TTR heated in the presence 
and absence of diflunisal.  Proteins were pre-incubated with and without 
diflunisal in PBS for 2 hours at 25 oC; all samples were subsequently incubated 
at 80 oC with shaking at 200 rpm for 24 hours, cross-linked with glutaraldehyde, 
and subjected to SDS-PAGE followed by Coomassie staining. 
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To further explore the stabilizing effect of diflunisal on the TTR tetramers, 
we compared unfolding of TTRdupES and L55P TTR in the presence and 
absence of the drug. The near-UV CD spectra were recorded while the samples 
were incubated at 80 ºC over the course of 60 minutes (Figure 11). Changes in 
the CD signal with a maximum at 291 nm corresponding to the Trp79 residue 
reports directly on the changes in the tertiary structure of the monomer upon 
heating (Kelly et al., 2005). TTRdupES unfolds much faster and to a higher 
degree than L55P TTR (Figure 11A and 11B). Both TTRdupES and L55P TTR 
elicited positive responses to diflunisal (Figure 11C and 11D). The kinetics of the 
protein unfolding process is shown by plotting the values of the CD signals at 291 
nm against the time points (Figure 12). The comparison of protein unfolding 
kinetics demonstrates that TTRdupES exhibits a greater overall recovery in CD 
signal upon the addition of diflunisal.  
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Figure 11.  Near UV-visible CD spectra of TTRdupES and L55P TTR in the 
presence and absence of diflunisal. 
(A) TTRdupES, (B) TTR L55P, (C) TTRdupES with diflunisal, and (D) TTR L55P 
with diflunisal recorded during heating at 80 oC. 
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Figure 12.  Kinetics of tertiary structure unfolding of TTRdupES and L55P 
TTR in the presence and absence of diflunisal.  Samples were incubated at 
80 oC with and without diflunisal and removed at time intervals between 0 and 60 
minutes for CD measurements at 291 nm. The CD data from signals obtained at 
291 nm were plotted against the individual time points. 
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DISCUSSION  
Analysis of patient serum from initial and follow-up clinical evaluations 
confirmed the presence of tetrameric TTR in all three samples. Compared to 
control serum, the levels of TTR were markedly lower in the patient with 
TTRdupES variant at all visits. This finding is consistent with published reports 
showing that patients with ATTRm have been found to have lower TTR serum 
levels compared to healthy individuals (Chan et al., 2017). It is not completely 
understood why serum TTR levels are reduced in patients with ATTRm, but 
several mechanisms have been proposed. These include the possibility of higher 
clearance of mutant protein, reduced liver secretion in response to higher 
misfolded TTR load, and less likely cytokine suppression of TTR transcription in 
the presence of chronic inflammation secondary to autonomic neuropathy 
(Buxbaum et al., 2010). 
One of the goals of the present study was to generate a recombinant TTR 
protein with the newly discovered mutation of interest (TTR Glu51_Ser52), and to 
characterize the biophysical properties of the protein, as well as compare these 
biophysical data to those obtained on wild-type TTR and the most unstable 
amyloidogenic variant, TTR L55P. Our results from SDS-PAGE analysis of TTR 
tetramer stability, under varying conditions and at different time intervals, 
indicated that the TTR Glu51_Ser52dup mutant is substantially more unstable 
than the wild-type protein or even the L55P TTR mutant. Loss of tetrameric state 
was identifiable within 1 hour when the Glu51_Ser52dup mutant protein was 
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subjected to heat denaturing conditions (80 °C). Heterotetramers formed by 
subunit exchange in mixtures of the wild-type and TTRdupES showed that the 
stability of the tetramers decreased with increased amounts of the mutant. This 
suggests that subunits of the mutant have an overall destabilizing effect on wild-
type monomers when present together in tetrameric form as likely would be the 
case in a patient heterozygous for the amyloidogenic mutation. Comparison of 
TTRdupES to the L55P TTR mutant in our biophysical and biochemical studies 
was important as the latter protein is considered to be the most unstable and 
amyloidogenic of all TTR proteins (Kon et al., 2015). ATTRm associated with 
L55P TTR is reported to be a very aggressive form of amyloid disease, and 
interestingly, our data suggest that TTRdupES was less stable. 
 Circular dichroism analysis demonstrated the marked difference in stability 
between wild-type TTR and the TTRGlu_51Ser52dup mutant. Thermal 
denaturation demonstrated a decreased stability of the mutant, with the protein 
unfolding at lower temperatures compared to the wild-type and L55P TTR. Also, 
the unfolding was evident in a very short time interval. The loss of native 
structure was observed in the near UV wavelength range, a wavelength interval 
that can be used to observe changes in the structural environment of aromatic 
amino acid side chains (Kelly et al., 2005). These residues include tryptophan, 
tyrosine, and phenylalanine which are all present in the TTR polypeptide chain. 
Tryptophan has a peak absorbance at approximately 290 nm where we observed 
greater structural changes in the TTRdupES protein compared to TTR L55P 
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(Kelly and Price, 2000). Although CD monitoring the near UV wavelength range 
may not be able to tell us about the overall structure of a protein, it does provide 
information when comparing two or more variants of the same protein (Kelly et 
al., 2005). Stabilization of all TTR proteins was observed when each was 
incubated with the TTR tetramer stabilizing drug, diflunisal; the effects seemed 
most dramatic with the TTRdupES protein. 
 In summary, results of the studies reported in this thesis demonstrate that 
the recombinant TTR variant protein, Glu51_Ser52dup, is less stable in vitro 
compared to recombinant wild-type TTR, as well as the amyloid-forming TTR 
mutant, L55P. Future studies of the structural dynamics, as well as the binding 
kinetics are required to more fully understand the amyloidogenic nature of the 
mutant protein and the relationship of the two inserted amino acid residues on 
the molecular structure of this highly unstable TTR protein variant. 
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